Shingrix Archives -

GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against

GSK beats forecasts, thanks to COVID antibody and Shingrix sales

https://pharmaphorum.com/news/gsk-beats-forecasts-thanks-to-covid-antibody-and-shingrix-sales/

News/ News/ R&D

Vaccines upstart Curevo has designs on blockbuster GSK franchise

Phil Taylor Curevo, financing, GlaxoSmithKline, shingles, Shingrix, vaccine 0 Comment

Seattle, US vaccine startup Curevo has raised $60 million in first-round financing that it says will be used

Vaccines upstart Curevo has designs on blockbuster GSK franchise

https://pharmaphorum.com/news/vaccines-upstart-curevo-has-designs-on-blockbuster-gsk-franchise/

News/ News/ R&D

Look out GSK, Pfizer and BioNTech are coming for Shingrix

Phil Taylor GlaxoSmithKline, mRNA, partnering, Pfizer, shingles, Shingrix, vaccine 0 Comment

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion.

Look out GSK, Pfizer and BioNTech are coming for Shingrix

https://pharmaphorum.com/news/look-out-gsk-pfizer-and-biontech-are-coming-for-shingrix/

Market Access/ News/ News

GSK wants to double Shingrix sales, and a new FDA okay could help

Phil Taylor GlaxoSmithKline, regulatory approval, shingles, Shingrix 0 Comment

The FDA has approved GlaxoSmithKline’s shingles vaccine Shingrix for use in people aged under 50 who are immunocompromised

GSK wants to double Shingrix sales, and a new FDA okay could help

https://pharmaphorum.com/news/gsk-wants-to-double-shingrix-sales-and-a-new-fda-okay-could-help/

News/ News/ Sales and Marketing

Vaccine sales recover at GSK in Q3, but lockdown fears weigh on shares

Phil Taylor coronavirus, coronavirus vaccine, COVID-19, financial results, GlaxoSmithKline, Shingrix, Trelegy 0 Comment

GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the

Vaccine sales recover at GSK in Q3, but lockdown fears weigh on shares

https://pharmaphorum.com/news/vaccine-sales-recover-at-gsk-in-q3-but-lockdown-fears-weigh-on-shares/

News/ News/ Sales and Marketing

GSK starts 2020 on a high, but warns of tougher times ahead

Phil Taylor coronavirus, financial results, GlaxoSmithKline, Shingrix, Zejula 0 Comment

GlaxoSmithKline saw its sales surge in the first three months of the year, with the coronavirus pandemic giving

GSK starts 2020 on a high, but warns of tougher times ahead

https://pharmaphorum.com/news/gsk-starts-2020-on-a-high-but-warns-of-tougher-times-ahead/

News/ News/ Sales and Marketing

Shingrix and Trelegy shield GSK from Advair fallout

Phil Taylor Advair, financial results, GlaxoSmithKline, Nucala, Shingrix, Trelegy 0 Comment

GlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs

Shingrix and Trelegy shield GSK from Advair fallout

https://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/

News/ News/ Sales and Marketing

Shingles vaccine boosts GSK as generic Advair bites

George Underwood Advair, GlaxoSmithKline, GSK, Q1, Shingrix 0 Comment

GSK’s first quarter sales beat estimates, helped along by shingles vaccine Shingrix and partly offsetting the effect of

Shingles vaccine boosts GSK as generic Advair bites

https://pharmaphorum.com/news/shingles-vaccine-boosts-gsk-as-generic-advair-bites/

Healthcare/ Market Access/ News/ News/ Pharma Market Access/ US

FDA approval gained, Glaxo awaits key committee blessing for Shingrix

Andrew McConaghie GSK, Shingrix 0 Comment

The FDA granted approval to GSK’s new shingles vaccine Shingrix on Friday, giving the company the green light

FDA approval gained, Glaxo awaits key committee blessing for Shingrix

https://pharmaphorum.com/news/shingrix-approved-glaxo-awaits-cdc-decision/

Trending

Shingrix

Login